In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antitrust Enforcement In Health Care: A Risky And Evolving Landscape

Executive Summary

In the last 18 months, seven companies and four executives in the generic pharmaceuticals manufacturing sector were charged with antitrust violations, amassing penalties of over $426m. And this month, the Department of Justice Antitrust Division brought its first ever criminal charges for a conspiracy to lower wages to workers against the former owner of a physical therapist staffing company. With enforcement efforts ramping up – and COVID-19 adding additional scrutiny – health care companies will need a comprehensive antitrust compliance program to avoid enforcement actions.

You may also be interested in...



Pink Sheet Podcast: Drug Pricing Campaign Future, Lilly’s Instagram Issue, Drug Withdrawal … Or Not

Pink Sheet reporters and editors discuss whether a new report on generic drug prices will affect efforts to green-light government price negotiations, Eli Lilly’s untitled letter for promotion on Instagram, and Oncopeptides deciding to withdraw its accelerated approval withdrawal.

QUOTED. Chamath Palihapitiya.

Akili Interactive Labs, which developed the first prescription-only video-game-based platform to be cleared for marketing by the US FDA, recently announced plans to go public through a SPAC merger with Social Capital Suvretta Holdings Corp. I. See what Chamath Palihapitiya, CEO of Social Capital and CEO of Social Capital Holdings Corp. I, said about it here.

BMS’ Cell Therapy For Lymphoma On Track For EU-Wide Approval

Several new drugs are now on track for an EU marketing authorization after getting the EMA’s thumbs up this week. 

Topics

Related Companies

UsernamePublicRestriction

Register

IV124669

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel